Latest & greatest articles for adalimumab

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on adalimumab or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on adalimumab and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for adalimumab

101. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs (Abstract)

Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs To compare the efficacy, safety, and tolerability of 5 doses of oral tofacitinib (CP-690,550) or adalimumab monotherapy with placebo for the treatment of active rheumatoid arthritis (RA) in patients with an inadequate response to disease-modifying antirheumatic (...) drugs.In this 24-week, double-blind, phase IIb study, patients with RA (n = 384) were randomized to receive placebo, tofacitinib at 1, 3, 5, 10, or 15 mg administered orally twice a day, or adalimumab at 40 mg injected subcutaneously every 2 weeks (total of 6 injections) followed by oral tofacitinib at 5 mg twice a day for 12 weeks. The primary end point was the responder rate according to the American College of Rheumatology 20% improvement criteria (ACR20) at week 12.Treatment with tofacitinib

2012 EvidenceUpdates Controlled trial quality: predicted high

102. Adalimumab for the treatment of moderate to severe ulcerative colitis (terminated appraisal) (TA262)

Adalimumab for the treatment of moderate to severe ulcerative colitis (terminated appraisal) (TA262) Adalimumab for the treatment of moderate to severe ulcerative colitis | Guidance | NICE Adalimumab for the treatment of moderate to severe ulcerative colitis Technology appraisal [TA262] Published date: 25 July 2012 Guidance This guidance has been updated and replaced by . Explore © NICE [year]. All rights reserved. Subject to .

2012 National Institute for Health and Clinical Excellence - Technology Appraisals

103. Efficacy and safety of adalimumab for the treatment of peripheral arthritis in spondyloarthritis patients without ankylosing spondylitis or psoriatic arthritis Full Text available with Trip Pro

Efficacy and safety of adalimumab for the treatment of peripheral arthritis in spondyloarthritis patients without ankylosing spondylitis or psoriatic arthritis To evaluate the efficacy and safety of adalimumab in patients with peripheral spondyloarthritis (SpA) not fulfilling the criteria for ankylosing spondylitis (AS) or psoriatic arthritis (PsA).40 patients with active peripheral SpA fulfilling the European Spondyloarthropathy Study Group or Amor criteria but not the criteria for AS or PsA (...) were included in a randomised, double-blind, placebo-controlled clinical trial. Patients were treated 1 : 1 with adalimumab or placebo for 12 weeks, followed by an open label extension up to week 24. Safety and efficacy measurements were performed every 6 weeks, with the patient's global assessment of disease activity at week 12 as the primary endpoint.At week 12, the patient's and physician's global assessment of disease activity, swollen joint count, Bath Ankylosing Spondylitis Disease Activity

2012 EvidenceUpdates Controlled trial quality: predicted high

104. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. Full Text available with Trip Pro

Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. Tofacitinib (CP-690,550) is a novel oral Janus kinase inhibitor that is being investigated for the treatment of rheumatoid arthritis.In this 12-month, phase 3 trial, 717 patients who were receiving stable doses of methotrexate were randomly assigned to 5 mg of tofacitinib twice daily, 10 mg of tofacitinib twice daily, 40 mg of adalimumab once every 2 weeks, or placebo. At month 3, patients in the placebo group who did not have (...) adalimumab (47.2%) than among those receiving placebo (28.3%) (P<0.001 for all comparisons). There were also greater reductions in the HAQ-DI score at month 3 and higher percentages of patients with a DAS28-4(ESR) below 2.6 at month 6 in the active-treatment groups than in the placebo group. Adverse events occurred more frequently with tofacitinib than with placebo, and pulmonary tuberculosis developed in two patients in the 10-mg tofacitinib group. Tofacitinib was associated with an increase in both low

2012 NEJM Controlled trial quality: predicted high

105. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial Full Text available with Trip Pro

Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial The aim of this study was to assess the efficacy and safety of adalimumab (ADA), a recombinant human monoclonal antibody against tumour necrosis factor α (TNF), for the induction of clinical remission in anti-TNF naïve patients with moderately to severely active ulcerative colitis.This 8-week, multicentre, randomised, double-blind, placebo-controlled study

2011 EvidenceUpdates Controlled trial quality: predicted high

106. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation

Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation Rodgers M, Epstein D, Bojke L, Yang H, Craig D, Fonseca T, Myers L, Bruce I, Chalmers R, Bujkiewicz S, Lai M, Cooper N, Abrams (...) K, Spiegelhalter D, Sutton A, Sculpher M, Woolacott N Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Rodgers M, Epstein D, Bojke L, Yang H, Craig D, Fonseca T, Myers L, Bruce I, Chalmers R, Bujkiewicz S, Lai M, Cooper N, Abrams K, Spiegelhalter D, Sutton A, Sculpher M, Woolacott N. Etanercept, infliximab and adalimumab for the treatment

2011 Health Technology Assessment (HTA) Database.

107. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor: a systematic review and economic evaluation

Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor: a systematic review and economic evaluation Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor: a systematic review and economic evaluation Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF (...) inhibitor: a systematic review and economic evaluation Malottki K, Barton P, Tsourapas A, Uthman AO, Liu Z, Routh K, Connock M, Jobanputra P, Moore D, Fry-Smith A, Chen YF Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Malottki K, Barton P, Tsourapas A, Uthman AO, Liu Z, Routh K, Connock M, Jobanputra P, Moore D, Fry-Smith A, Chen YF. Adalimumab

2011 Health Technology Assessment (HTA) Database.

108. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-a) inhibitors, adalimumab and infliximab, for CrohnÔ??s disease

A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-a) inhibitors, adalimumab and infliximab, for CrohnÔ??s disease A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-a) inhibitors, adalimumab and infliximab, for Crohn's disease A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-a) inhibitors, adalimumab and infliximab, for Crohn's disease Dretzke J, Edlin R, Round J (...) , Connock M, Hulme C, Czeczot J, Fry-Smith A, McCabe C, Meads C Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Dretzke J, Edlin R, Round J, Connock M, Hulme C, Czeczot J, Fry-Smith A, McCabe C, Meads C. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-a) inhibitors, adalimumab and infliximab, for Crohn's

2011 Health Technology Assessment (HTA) Database.

109. Adalimumab in severe and acute sciatica: A multicentre, randomised, double-blind, placebo-controlled trial Full Text available with Trip Pro

Adalimumab in severe and acute sciatica: A multicentre, randomised, double-blind, placebo-controlled trial Based on several experimental results and on a preliminary study, a trial was undertaken to assess the efficacy of adalimumab, a tumor necrosis factor alpha inhibitor, in patients with radicular pain due to lumbar disc herniation.A multicenter, double-blind, randomized controlled trial was conducted between May 2005 and December 2007 in Switzerland. Patients with acute (duration of <12 (...) weeks) and severe (Oswestry Disability Index score of >50) radicular leg pain and imaging-confirmed lumbar disc herniation were randomized to receive as adjuvant therapy either 2 subcutaneous injections of adalimumab (40 mg) at 7-day intervals or matching placebo. The primary outcome was the score for leg pain, based on a visual analog scale (0-100 mm), which was recorded every day for 10 days and at 6 weeks and 6 months.Of the 265 patients screened, 61 were enrolled; 31 patients were assigned

2010 EvidenceUpdates Controlled trial quality: predicted high

110. Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial Full Text available with Trip Pro

Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial In early and active RA despite MTX, continuous treatment with TNF blockers in combination with MTX is recommended. To compare this strategy with an initial combination of MTX and adalimumab (ADA) given for 3 months and then adjusted based on the disease activity status.Prospective unblinded randomized multicentre

2010 EvidenceUpdates Controlled trial quality: uncertain

111. Infliximab (review) and adalimumab for the treatment of Crohn's disease (TA187)

Infliximab (review) and adalimumab for the treatment of Crohn's disease (TA187) Overview | Infliximab and adalimumab for the treatment of Crohn's disease | Guidance | NICE Infliximab and adalimumab for the treatment of Crohn's disease Technology appraisal guidance [TA187] Published date: 19 May 2010 Share Save Guidance on infliximab (Remicade) and adalimumab (Humira) for treating severe active Crohn's disease in adults. The recommendations also apply to biosimilar products of the technologies

2010 National Institute for Health and Clinical Excellence - Technology Appraisals

112. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (TA199)

Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (TA199) Overview | Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis | Guidance | NICE Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis Technology appraisal guidance [TA199] Published date: 25 August 2010 Share Guidance on etanercept (Enbrel), infliximab (Remicade) and adalimumab (Humira) for treating active and progressive psoriatic arthritis in adults (...) . The recommendations also apply to biosimilar products of these technologies that have a marketing authorisation allowing the use of the biosimilar for the same indication. This guidance replaces NICE technology appraisal guidance on: etanercept and infliximab for the treatment of psoriatic arthritis (TA104) and adalimumab for the treatment of psoriatic arthritis (TA125). Guidance development process Next review date: This guidance will be reviewed if there is new evidence. Your responsibility The recommendations

2010 National Institute for Health and Clinical Excellence - Technology Appraisals

113. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (TA195)

Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (TA195) Overview | Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor | Guidance | NICE Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor Technology appraisal guidance [TA195 (...) ] Published date: 25 August 2010 Share Guidance on adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade), rituximab (MabThera) and abatacept (Orencia). These drugs are for adults with severe rheumatoid arthritis who have tried other disease-modifying antirheumatic drugs (DMARDs) but cannot tolerate them or they haven’t worked well enough. The recommendations also apply to biosimilar products of these technologies that have a marketing authorisation allowing the use of the biosimilar for the same

2010 National Institute for Health and Clinical Excellence - Technology Appraisals

114. Humira (Adalimumab) (Abbott Laboratories) for treatment of pediatric crohn disease

Humira (Adalimumab) (Abbott Laboratories) for treatment of pediatric crohn disease Humira (Adalimumab) (Abbott Laboratories) for treatment of pediatric crohn disease Humira (Adalimumab) (Abbott Laboratories) for treatment of pediatric crohn disease Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Humira (Adalimumab) (Abbott Laboratories) for treatment

2010 Health Technology Assessment (HTA) Database.

115. A systematic review and meta-analysis of the efficacy and safety of adalimumab for treating rheumatoid arthritis

A systematic review and meta-analysis of the efficacy and safety of adalimumab for treating rheumatoid arthritis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.

116. Systematic review: the short-term and long-term efficacy of adalimumab following discontinuation of infliximab

Systematic review: the short-term and long-term efficacy of adalimumab following discontinuation of infliximab Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

117. Adalimumab (Humira) for Crohns Disease

Adalimumab (Humira) for Crohns Disease Adalimumab (Humira) for Crohns Disease Adalimumab (Humira) for Crohns Disease Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Report may be purchased from . Citation Adalimumab (Humira) for Crohns Disease . Lansdale: HAYES, Inc.. 2009 Authors' objectives Adalimumab (D2E7, Humira®; Abbott Laboratories) is a recombinant human

2009 Health Technology Assessment (HTA) Database.

118. Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis Full Text available with Trip Pro

Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis Xie F, Blackhouse G, Assasi N, Gaebel K, Robertson D, Goeree R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods (...) strategies were usual care, infliximab 5mg per kg with a switch to adalimumab if there was no response or if the response was lost during maintenance therapy, and infliximab 5mg per kg with a switch to 10mg per kg if there was no response and a switch to adalimumab if the response was lost during maintenance therapy. Both the infliximab and adalimumab strategies consisted of initial treatment at weeks zero, two, and six, followed by maintenance treatment every eight weeks. The usual care was conventional

2009 NHS Economic Evaluation Database.

119. Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn's disease

Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn's disease Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 NHS Economic Evaluation Database.

120. Adalimumab - Psoriasis

Adalimumab - Psoriasis Common Drug Review CEDAC Meeting – September 17, 2008 Page 1 of 3 Notice of CEDAC Final Recommendation – October 16, 2008 © 2008 CADTH CEDAC FINAL RECOMMENDATION and REASONS for RECOMMENDATION ADALIMUMAB (Humira ® – Abbott Laboratories Ltd.) NEW INDICATION: PSORIASIS Description: Adalimumab is a human monoclonal antibody tumour necrosis factor (TNF). The basis of this resubmission is a new indication. Adalimumab is indicated for the treatment of adult patients (...) with chronic moderate to severe psoriasis who are candidates for systemic therapy. For patients with chronic moderate plaque psoriasis, adalimumab should be used after phototherapy has been shown to be ineffective or inappropriate. Previous CEDAC Recommendations for Adalimumab: • Rheumatoid arthritis (see Notice of CEDAC Final Recommendation, February 11, 2005) • Psoriatic arthritis (see Notice of CEDAC Final Recommendation, November 29, 2006) • Ankylosing spondylitis (see Notice of CEDAC Final

2008 Canadian Agency for Drugs and Technologies in Health - Common Drug Review